Details

Autor(en) / Beteiligte

• BORODY, T. J.
• PANG, G.
• WETTSTEIN, A. R.
• CLANCY, R.
• HERDMAN, K.
• SURACE, R.
• LLORENTE, R.
• NG, C.

Titel

Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection

Ist Teil von

• Alimentary pharmacology & therapeutics, 2006-02, Vol.23 (4), p.481-488

Ort / Verlag

Oxford, UK: Blackwell Science Ltd

Erscheinungsjahr

2006

Quelle

Wiley Blackwell Single Titles

Beschreibungen/Notizen

• Summary Background  Current ‘rescue’ therapies provide inadequate Helicobacter pylori eradication rates because of antibiotic resistance. Aim  To test the efficacy of a modified triple regimen combining rifabutin, pantoprazole and amoxicillin as rescue therapy for patients in whom eradication of H. pylori had failed standard clarithromycin‐based triple therapy. Methods  One hundred and thirty patients (mean age 51.7 ± 14.8 years) who had failed one or more eradication attempts with omeprazole, clarithromycin and amoxicillin were treated for 12 days with rifabutin 150 mg daily, amoxicillin 1 g or 1.5 g t.d.s, and pantoprazole 80 mg t.d.s. Results  The intention‐to‐treat and per‐protocol eradication rates were 90.8/90.8%. Metronidazole or/and clarithromycin resistance had no significant impact on H. pylori eradication rates. A higher overall eradication rate of 96.6% (95% CI: 92.1–101%) was obtained in patients treated with a regimen containing 1.5 g amoxicillin t.d.s compared with 90.7% (95% CI: 82–98.6%) using a regimen with 1 g amoxicillin t.d.s but the difference was not significant. Side‐effects reported in 40% of patients were mild. Conclusion  A 12‐day course of low dose of rifabutin with an increased dose of amoxicillin and pantoprazole is well‐tolerated and highly effective against dual‐resistant H. pylori infection after failure of triple therapy.